Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Eli Lilly and Company LLY announced that its executive vice president and chief financial officer (CFO) Anat Ashkenazi has resigned after serving for 23 years at the company. Ashkenazi has joined Google's parent company Alphabet GOOGL as CFO and senior vice president, effective Jul 31, 2024.

Eli Lilly (LLY) Veteran Anat Ashkenazi to Join Alphabet as CFO

A panel of outside experts to the U.S. health regulator will vote on Monday on whether data for Eli Lilly's experimental treatment, donanemab, shows it is effective for treating patients with early Alzheimer's disease.

US FDA panel to vote on data, risk profile of Lilly Alzheimer's drug

Abercrombie & Fitch

ARM Holdings PLC

Cava Group, Inc.

Carvana

Robinhood

Spotify

Growth stocks continue to drive the market and investor portfolios higher. Several companies with strong catalysts are seeing their sales and profits rise, and that is pushing their share prices to new heights.

Growth Stock Goliaths: 7 Picks That Will Tower Over the Competition

Costco

Flutter Entertainment PLC

First Solar

Marvell Technology

Pure Storage

Xylem

There's certainly some level of comfort in bidding up the same names as everybody else. But the most satisfying returns stem from momentum stocks that you identified before the big wave.

Mid-Year Momentum Plays: 7 Stocks to Buy for the Second Half

Alphabet

Google stock is a mutual fund favorite and is near a buy point. Two other leading growth stocks top the list of fund favorites.

Google And Eli Lilly Have Things In Common Besides Being Mutual Fund Favorites

Eli Lilly has been outperforming the S&P 500. The company's blockbuster drug Mounjaro has been approved in China, resulting in high demand and a strong earnings report. The five-year target price for Eli Lilly has been raised to $1,455 based on conservative earnings projections and a multiple of 40X.

Is It Possible Eli Lilly Is Breaking Out To New All-Time Highs?

INDIANAPOLIS , June 5, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Anat Ashkenazi has resigned as chief financial officer to pursue a career opportunity outside of the pharmaceutical industry. "On behalf of our board of directors, leadership team and employees, I would like to thank Anat for her 23 years of outstanding service to our company," said David A.

Lilly announces departure of Anat Ashkenazi, chief financial officer

Citigroup

Johnson Controls

Progressive

For this month, the cycle/relative strength concept is applied. First, the S&P 500 stocks are ranked from the best performer to the worst by calculating the expected return in that month.

S&P Stocks To Trade In June

The National Institute for Health and Care Excellence (NICE) in England has approved a second drug to combat obesity, offering a more effective alternative to semaglutide. The newly approved drug, tirzepatide, marketed as Mounjaro in the UK, is recommended for very obese individuals with a body mass index (BMI) of at least 35 and at least one weight-related comorbidity, such as heart disease, type 2 diabetes, or sleep apnea.

Mounjaro becomes second weight loss drug to receive NICE green light

Eli Lilly and Company (NYSE:LLY ) Lilly Oncology ASCO Investor Event June 2, 2024 8:30 PM ET Company Participants Jake Van Naarden - Executive VP & President of Loxo Lillian Smyth - Senior Vice President and Global Development Head for Breast Cancer at Loxo John Pagel - Vice President and Head of Global Hematology at Loxo Geoff Oxnard - VP of Clinical Development, Global Head Thoracic Cancer at Loxo Arjun Balar - MD, Vice President, Global Clinical Development at Loxo Barry Taylor - Chief Scientific Officer of Loxo Kara Clinton - Senior Vice President Oncology Medical Affairs Winselow Tucker - Senior Vice President & Chief Commercial Officer for Loxo Conference Call Participants Evan Seigerman - BMO Capital Markets Seamus Fernandez - Guggenheim Securities Geoff Meacham - Bank of America Steve Scala - TD Cowen Chris Schott - JPMorgan Akash Tewari - Jefferies Dave Risinger - Leerink Partners Jake Van Naarden All right. Can everyone hear me, yes.

Eli Lilly and Company (LLY) Lilly Oncology ASCO Investor Event (Transcript)

Britain's medical costs regulator on Tuesday recommended Eli Lilly's weight-loss drug Mounjaro for some patients with obesity and suggested not placing a time limit on the medicine's use as it had for rival Novo Nordisk's Wegovy.

Britain considers offering Lilly weight-loss drug on better terms than Wegovy

INDIANAPOLIS , June 4, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Melissa Seymour will join the company as executive vice president of Global Quality and member of the company's Executive Committee, effective July 22, 2024. Seymour currently serves as the chief quality officer for Bristol Myers Squibb and succeeds Johna Norton, whose retirement after 34 years of service was announced earlier this year.

Melissa Seymour to join Lilly as executive vice president of Global Quality

The profit zone ranges between 757.15 and 912.85.

LLY Stock Today: How To Trade An Unbalanced Iron Condor That May Put $285 In Your Pocket

Advanced Micro Devices

NVIDIA

Novo Nordisk

Taiwan Semiconductor Manufacturing

As Nvidia stock takes aim at another record high and market-cap dominance, AMD and TSM set up alongside two top drugmakers.

Beyond The Nvidia Juggernaut: 2 Chip Giants, 2 Drugmakers In Spotlight

One of Eli Lilly's anti-obesity candidates reported positive data in a phase 3 study. The results highlight the strong breadth of Lilly's portfolio in this promising area.

Watch Out Wegovy: Here Comes Another Promising Anti-Obesity Candidate

Bristol-Myers

Chevron

Enbridge

Enterprise Products Partners

Energy Transfer LP Unit

Kinder Morgan

National Retail Properties

Realty Income Corp

Pfizer

Prologis

Rexford Industrial Realty

W. P. Carey

Exxon Mobil

Amazon CEO Andy Jassy highlights key traits for success in a career professional, including working hard, being can-do, and following through on commitments. There are different paths to success, and income investors can potentially achieve a high level of success by buying quality undervalued companies that pay dividends. In this article, I highlight high-yielding names in REITs, Energy, and Healthcare that I find attractive at present.

Earn An 'Embarrassing' Amount Of Cash Flow From These Contrarian Picks

Aflac

Birkenstock Holding Plc

NetApp

Despite the market's dramatic sell-off on Friday, some stocks showed impressive strength by making new 52-week highs. While big tech led the market decline, these four stocks, Birkenstock, NetApp, Eli Lilly, and Aflac, demonstrated resilience and robust performance, along with displaying overall relative strength to the market and their respective sectors.

Four Stocks Making New Highs Despite Market Weakness

Eli Lilly and Novo Nordisk are leaders in fast-growing therapeutic areas. Both companies have excellent track records of innovations and solid results.

Prediction: These Could Be the Best-Performing Pharmaceutical Stocks Through 2030

The anti-obesity drug market will be worth $130 billion by 2030, Goldman Sachs said. New products such as Eli Lilly's Zepbound prompted the bank to raise its forecast.

Eli Lilly's Wegovy rival Zepbound will help make weight-loss drug market worth $130 billion by 2030, Goldman Sachs says

Eli Lilly announced impressive Q1 2024 financial results, with revenue surging by 26% YoY and exceeding expectations for earnings per share. The company raised its full-year 2024 revenue guidance and adjusted earnings per share guidance. While facing challenges with the price of its stock and supply chain issues, Eli Lilly anticipates significant increases in shipment volumes in the second half of 2024.

Eli Lilly's Growth And Challenges: A Cautious Buy

Eli Lilly and Novo Nordisk have generated incredible returns for investors in the past few years. The surging popularity of their weight loss treatments has produced a lot of bullishness.

This Is the Biggest Risk for Eli Lilly and Novo Nordisk Investors

Intuitive Surgical

Universal Health Services

Vertex Pharmaceuticals

Eli Lilly is in a buy zone, while weight-loss drug rival Novo Nordisk just forged a lower entry.

S&P 500 Giants Lead Five Healthy Stocks Near Buy Points

Data demonstrated promising monotherapy activity with olomorasib across a range of KRAS G12C-mutant solid tumors, including non-small cell lung cancer, and a tolerability profile in combination with pembrolizumab that is well-suited to first-line lung cancer development INDIANAPOLIS , June 1, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced updated data from the Phase 1/2 clinical trial evaluating olomorasib as a monotherapy in patients with KRAS G12C-mutant advanced solid tumors and in combination with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with KRAS G12C-mutant advanced non-small cell lung cancer (NSCLC). Olomorasib is an investigational, oral, potent, and highly selective second-generation inhibitor of the KRAS G12C protein.

Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO® Annual Meeting

Uber

Although there is no hard-and-fast rule about what constitutes a blue-chip stock, they all tend to have certain qualities. They are large, financially stable companies that have been through numerous business and economic cycles that proved their worth in the end.

News for Eli Lilly Stock (LLY)